Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens.
CONCLUSION: The study demonstrates that the SUVmax was significantly associated with PD-L1 expression in NSCLC and ADC. The SUVmax was significantly different between the PD-L1 high and low expression conditions, as quantified using a PD-L1 22C3 assay.
ADVANCES IN KNOWLEDGE: This study provides direct evidence that SUVmax as a metabolic biomarker may help select patients with NSCLC likely to benefit from pembrolizumab.
PMID: 33492995 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Zhao L, Liu J, Wang H, Shi J Tags: Br J Radiol Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | CT Scan | Lung Cancer | Non-Small Cell Lung Cancer | PET Scan | Radiology | Study | UK Health